Ming Poi

Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (5)

Phosphatidylinositol 3-kinase delta (PI3Kδ) promotes tumour cell growth directly or indirectly by activating immune-suppressive cells. Roginolisib is a selective, non-ATP competitive inhibitor, which locks PI3Kδ into an inactive state. In a First-in-Human dose study, continuous daily dosing of roginolisib was investigated in patients with solid and haematologic malignancies. In Part A, 24 patients received escalating doses of roginolisib. In Part B, 20 mostly pre-treated metastatic uveal melanoma (mUM) patients received a dose associated with continuous PI3Kδ inhibition of > 90%. No Dose Limiting Toxicity or drug related toxicities requiring dose modifications were observed (≥ Grade 3 toxicities: 3/44; 6.8%). In mUM, median Overall Survival (mOS) was 20.8 months. mOS in mUM patients with Stable Disease was 28.5 months, and in patients with Progressive Disease was 12.3 months. Roginolisib treatment was associated with reducing T regulatory cell abundance, increasing activated CD8 + T cells and soluble plasma IL-15.

Year:

2025

Supplementary Figure 2. Heatmap showing Spearman’s correlation matrix for pairwise comparisons of gene expression variables. Spearman’s correlation coefficient (r) values and associated color coding are shown only for correlations that were statistically significant (P

Year:

2025

Purpose: B7 homolog 3 (B7-H3) is a promising target for antibody–drug conjugates, with ifinatamab deruxtecan demonstrating an objective response rate of 54.8% in previously treated extensive-stage small cell lung cancer (SCLC). This analysis aimed to characterize B7-H3 RNA expression with reference to SCLC molecular subtypes (SCLC-A, SCLC-N, SCLC-P, and SCLC-I) and immune-related parameters. Experimental Design: Tumor RNA expression and mutational burden for 1,721 patients with SCLC were derived from a real-world database (Caris Life Sciences). A predominant molecular subtype was assigned based on RNA expression using a gene-ratio classifier. PD-L1 expression was assessed by IHC (antibody 22C3; positive cutoff: tumor proportion score ≥1%). Results: The predominant molecular subtype was SCLC-A in 848 (49.3%), SCLC-N in 202 (11.7%), SCLC-P in 142 (8.3%), SCLC-I in 291 (16.9%), and equivocal in 238 (13.8%) samples. B7-H3 expression was high and consistent among subtypes ( q > 0.05), whereas DLL3 and SEZ6 expression each differed significantly (both q B7-H3 expression quartiles (range, 39.2%–46.5%). Median (95% confidence interval) B7-H3 expression was comparable between patients with and without prior immunotherapy [18.7 (16.5–21.2) and 17.3 (16.4–18.1) transcripts per million, respectively]. B7-H3 was not correlated with a T-cell signature but showed a strong correlation with HAVCR2 / TIM3 , CD86 , PDCD1LG2 / PD-L2 , and M2 macrophages. Conclusions: B7-H3 showed consistent, high expression across SCLC molecular subtypes, whereas DLL3 and SEZ6 expression varied significantly. These data suggest that B7-H3–targeting antibody–drug conjugates may be active across SCLC subtypes, consistent with the high reported response rates.

Year:

2025

Supplementary Figure 4. Expression of B7-H3 in patients with PNET (n = 212), according to classification as low- or high-grade tumors based on MKI67/Ki-67 mRNA expression. Median age was 66 years (range, 19–89+) and 135 patients (63.7%) were female. Expression levels were quantified as log2(TPM +1). Boxplots indicate the median, interquartile range, and range of values, with diamonds representing outliers.

Year:

2025

Head and neck squamous cell carcinoma (HNSCC) accounts for over 10,000 deaths in the United States annually. Approximately 80% of HNSCC are human papillomavirus (HPV)‐negative which have an overall poorer prognosis compared to the HPV‐positive disease. Treatment options are mainly nontargeted chemotherapy, radiation, and surgery. The cyclin‐ d ‐CDK4/6‐RB pathway, which regulates cell cycle progression, is often deregulated in HNSCC, making it an attractive therapeutic target. In the current study, we investigated the therapeutic effects of cyclin‐dependent kinase 4/6 (CDK4/6) inhibitors in preclinical models of HNSCCs. Our results show that the specific CDK4/6 inhibitor, abemaciclib, inhibited cell growth, and induced apoptosis in HNSCC cell lines. We also demonstrated that both the pro‐survival autophagy pathway and the ERK pathway in HNSCC cells were activated with abemaciclib treatment through the generation of reactive oxygen species (ROS). Coinhibition of CDK4/6 and autophagy synergistically decreased cell viability, induced apoptosis, and inhibited tumor growth in both in vitro and in vivo preclinical HNSCC models. These results reveal a potential therapeutic strategy that supports the rationale for further clinical development of a combination of CDK4/6 and autophagy inhibitors in HNSCC.

Year:

2023

Collaborators (11)

Armando Santoro

Professore

Humanitas University

ITALY
View details

Carmelo Carlo‐Stella

IRCCS Humanitas Research Hospital

ITALY
View details

Lauren A. Byers

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Charles Rudin

Memorial Sloan Kettering Cancer Center

UNITED STATES
View details

Lakshmikanth Tadepally

Mass Cytometry Facility Head

Karolinska Institutet

SWEDEN
View details

Petter Brodin

Professor of Pediatric immunology

Imperial College London

UNITED KINGDOM
View details

Giusy Di Conza

University of Lausanne

SWITZERLAND
View details

Simon Heeke

Assistant Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Taofeek Owonikoko

Professor and Division Chief

University of Pittsburgh

UNITED STATES
View details

Pavlina Spiliopoulou

University of Glasgow

UNITED KINGDOM
View details

Michele Maio

-

ITALY
View details